ElectroCore Is Changing the Game in Bioelectronics
electroCore, a player in the bioelectronicâs market is on a mission to redefine the way patients are treated for migraines. The Basking Ridge, N.J.-based company recently launched the gammaCore Sapphire, a second-generation device that is non-invasive vagus nerve stimulator for the acute treatment of pain associated with migraine and episodic cluster headache.
The gammaCore Sapphire was cleared in December of 2017 but electroCore delayed the productâs launch.
âWe were waiting to launch the gammaCore Sapphire after we launched into migraine, which happened on July 1Â of this year,â Frank Amato, CEO of electroCore, told MD+DI. âWe were trying to time both our broad commercial launch across the U.S. in migraine with the new second-generation device.â
The proceeds from electroCoreâs IPO were used to help fund the launch of the product.
The handheld device is self-administered by patients and is placed on the neck over the vagus nerve. Amato noted if you can find your pulse on either side of your trachea then you can find where the vagus nerve is. Once the fibers of the vagus nerve are stimulated with the device, it reduces or relieves pain for the patient.
âThe first-generation device, gammaCore is a product that requires the patients to get a new device each month,â Amato said. âWith the sec...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Digital Health Source Type: news
More News: Arthritis | Brain | Chemistry | Headache | Medical Devices | Migraine | Neurology | Pain | Rheumatoid Arthritis | Rheumatology